ImmunityBio (IBRX) Net Margin (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Net Margin of 1431.45% for Q1 2026, down 64641.0% year-over-year from N/an in Q1 2025, and down 784.52% quarter-over-quarter from 161.83% in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Net Margin (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Net Margin for 13 consecutive years, with 1431.45% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 64641.0% year-over-year to 1431.45%; the TTM figure through Mar 2026 stood at 606.22% (up 70433.0% YoY), while the FY2025 annual figure was 310.25%, up 249508.0% from the prior year.
- Net Margin slipped to 1431.45% in Q1 2026 per IBRX's latest filing, from 161.83% in the prior quarter.
- Across five years, Net Margin topped out at 161.83% in Q4 2025 and bottomed at 735700.0% in Q1 2022.
- Historically, Net Margin has averaged 132741.67% across 5 years, with a median of 32384.17% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin plunged 67780000 bps — and 2023, when it soared 70331583 bps.
- ImmunityBio's Net Margin stood at 148391.78% in 2022, then declined by 13 bps to 167923.74% in 2023, then soared by 100 bps to 783.62% in 2024, then soared by 79 bps to 161.83% in 2025, then tumbled by 785 bps to 1431.45% in 2026.
- Business Quant data shows IBRX's Net Margin at 1431.45% in Q1 2026, 161.83% in Q4 2025, and 209.94% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -3.12% |
| 10 | ImmunityBio | 8.48 Bn | 8.12 Bn | 50.94 Mn | -449.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -449.63% |
| Mar 31, 2026 | -1,431.47% |
| Dec 31, 2025 | -161.83% |
| Sep 30, 2025 | -209.83% |
| Jun 30, 2025 | -350.44% |
| Mar 31, 2025 | -785.05% |
| Dec 31, 2024 | -783.62% |
| Sep 30, 2024 | -1,404.39% |
| Jun 30, 2024 | -12,854.25% |
| Mar 31, 2024 | -335,325.00% |
| Dec 31, 2023 | -167,923.74% |
| Sep 30, 2023 | -116,636.59% |
| Jun 30, 2023 | -337,104.88% |
| Mar 31, 2023 | -32,384.17% |
| Dec 31, 2022 | -148,391.78% |
| Sep 30, 2022 | -94,204.24% |
| Jun 30, 2022 | -270,957.14% |
| Mar 31, 2022 | -735,700.00% |
| Dec 31, 2021 | -23,475.13% |
| Sep 30, 2021 | -133,983.33% |